PERSONAL GENOMICS TAIWAN, INC.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
PERSONAL GENOMICS TAIWAN, INC. is primarily commissioned by Personal Genomics, Inc. (PGI) to conduct the research and development of compact nucleic acid sequencing platforms for clinical diagnosis. Its business areas include:
1. OES Single-Molecule Sequencer Development: This sequencer utilizes the principle of continuous single-molecule sequencing by synthesis, integrating technologies such as nano-optical chips, solid-phase single-molecule biochemical reactions, and single-molecule fluorescence cameras to develop a nucleic acid sequencer suitable for clinical diagnostic testing.
2. Single-Molecule Sequencing Chemical Enzyme and Reagent Development: Utilizing enzyme engineering methods to screen high-activity enzymes for specially designed fluorescently labeled nucleotides, and developing them into sequencing reagents and consumables.
(The content above was translated by AI.)
1. OES Single-Molecule Sequencer Development: This sequencer utilizes the principle of continuous single-molecule sequencing by synthesis, integrating technologies such as nano-optical chips, solid-phase single-molecule biochemical reactions, and single-molecule fluorescence cameras to develop a nucleic acid sequencer suitable for clinical diagnostic testing.
2. Single-Molecule Sequencing Chemical Enzyme and Reagent Development: Utilizing enzyme engineering methods to screen high-activity enzymes for specially designed fluorescently labeled nucleotides, and developing them into sequencing reagents and consumables.
(The content above was translated by AI.)
Founded Year
2010
Unified Business No.
53089067
Status
Active
Number of Employees
0
Total Paid-in
Capital
625,079,800 (NT$)
Location of Company
Taiwan
, Hsinchu County
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Ti-Xue Biotechnology Company is the product research and development base of Personal Genomics, Inc. (PGI) in Taiwan, dedicated to developing the most advanced "Single-molecule continuous DNA sequencer." Its key feature lies in integrating cross-disciplinary technologies such as nano-optical components, molecular bioinformatics and enzyme engineering, real-time observation and recording of single-molecule fluorescence, high-precision fluorescence cameras, and microfluidic instrument design, to develop a single-molecule nucleic acid sequencing platform required for the clinical diagnostics market. Once successful, it will expand the market scale of gene sequencing and its applications, driving unprecedented new business opportunities.
Personal Genomics, Inc. is a startup company invested in by domestic and foreign enterprises as well as venture capital funds, focusing on the development of innovative technologies in the field of nucleic acid sequencing, and holds more than 150 patents worldwide. Ti-Xue Biotechnology is its primary research and development base.
The term "Ti-Xue" comes from the Chinese translation of the English word "omics." Genomics, proteomics, and metabolomics have become prominent fields of study in life sciences since 2000. Ti-Xue technology allows us to explore organisms from a "holistic" and "systemic" perspective, explaining their operations, and also provides many new development opportunities such as disease diagnosis and treatment, new drug development, drug selection, agricultural breeding improvement, infectious disease control, and environmental conservation.
(The content above was translated by AI.)
Personal Genomics, Inc. is a startup company invested in by domestic and foreign enterprises as well as venture capital funds, focusing on the development of innovative technologies in the field of nucleic acid sequencing, and holds more than 150 patents worldwide. Ti-Xue Biotechnology is its primary research and development base.
The term "Ti-Xue" comes from the Chinese translation of the English word "omics." Genomics, proteomics, and metabolomics have become prominent fields of study in life sciences since 2000. Ti-Xue technology allows us to explore organisms from a "holistic" and "systemic" perspective, explaining their operations, and also provides many new development opportunities such as disease diagnosis and treatment, new drug development, drug selection, agricultural breeding improvement, infectious disease control, and environmental conservation.
(The content above was translated by AI.)
